Home / International / Life Sciences & Healthcare

Life Sciences & Healthcare

With more than 480 lawyers, patent attorneys, scientists and academics’ across CMS and the support of the Life Sciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences & healthcare sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Life Sci­ences & Health­care Sec­tor Group: glob­al CMS con­tacts
480+ law­yers, pat­ent at­tor­neys, sci­ent­ists and aca­dem­ics glob­ally
Glob­al Life Sci­ences & Health­care Fest­iv­al 2021 – Vir­tu­al – High­lights
The emer­gence of new and sus­tain­able tech­no­lo­gies
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With big deals fuel­ling re­cord levels of M&A activ­ity, a steady stream of in­nov­at­ive and dis­rupt­ive tech­no­lo­gies, new and in­creas­ingly com­plex reg­u­lat­ory chal­lenges and a thriv­ing start-up com­munity...
On the Pulse
Wel­come to CMS ‘On the Pulse’ video/pod­cast series for all Life Sci­ences & Health­care pro­fes­sion­als – leg­al, com­pli­ance, reg­u­lat­ory


Hun­gary makes changes to min­is­tries over­see­ing FDI con­trol mat­ters
Fol­low­ing the elec­tion and form­a­tion of a new gov­ern­ment in Hun­gary on 24 May 2022, the gov­ern­ment has ad­op­ted Gov­ern­ment De­cree No. 182/2022 (V. 24.) on the com­pet­ences and powers of the mem­bers of Gov­ern­ment...
AI, ma­chine learn­ing & big data laws and reg­u­la­tions 2022
The United King­dom has an am­bi­tion to be­come the world’s lead­er in Ar­ti­fi­cial In­tel­li­gence (AI) tech­no­logy and policy and AI is in­creas­ingly be­ing ad­op­ted across a wide vari­ety of sec­tors in­clud­ing...
Spot­light on UK Design Law: Part 3 – ‘Over­lap between copy­right and designs’
The UKIPO re­cog­nises that there is a lack of clar­ity on the ex­tent of over­lap between copy­right and design law, and how they should co-ex­ist. In par­tic­u­lar, the Call for Views notes the un­cer­tainty as...
CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
Why this guide? In re­cent years can­nabis trade and re­lated activ­ity has de­veloped in­to a growth busi­ness area. In the life sci­ences and health­care fields, there have been in­creases in the num­bers of...
CMS Ex­pert Guide to trade secrets
Ex­plore and com­pare the pro­tec­tion for trade secrets in your chosen mar­kets. As a busi­ness, your most val­ued as­sets can be the things you can’t touch or see.  In­tan­gible as­sets such as pat­ents, for­mu­las...
Spot­light on UK Design Law: Part 2 - Sim­pli­fy­ing the designs sys­tem
The UKIPO re­cog­nises that the cur­rent design frame­work is highly com­plex, in­volving three dif­fer­ent types of un­re­gistered rights (two of which ori­gin­ate from EU law) in ad­di­tion to re­gistered designs...
High­lights on Ad­min­is­trat­ive Pro­vi­sions on Drug An­nu­al Re­port­ing
The Na­tion­al Med­ic­al Products Ad­min­is­tra­tion ("NMPA") is­sued the Ad­min­is­trat­ive Pro­vi­sions on Drug An­nu­al Re­port­ing (“Pro­vi­sions”) on 11 April 2022, which took ef­fect on the same day. The Pro­vi­sions...
Fine-tun­ing Joint Tar­geted Area In­spec­tions - A new era?
Multi-agency Joint Tar­geted Area In­spec­tions ('J­TAI') are mak­ing a comeback. Ofs­ted, the Care Qual­ity Com­mis­sion ('C­QC') and Her Majesty's In­spect­or­ate of Con­stabu­lary and Fire & Res­cue Ser­vices ('H­M­IC­FRS')...
UKIPO Call for Views on designs re­gime
Spot­light on UK Design Law  Re­view­ing the UK designs frame­work – UKIPO’s Call for Views The leg­al pro­tec­tion of design rights in the UK is no pic­nic. As IP prac­ti­tion­ers and design busi­nesses will...
Com­ing up next in the Scot­tish Hos­pit­als In­quiry: May Hear­ings Com­mence
9 May 2022 marks the start of the next key stage in the Scot­tish Hos­pit­als In­quiry: the com­mence­ment of the diet of hear­ings that will cov­er the two broad themes of (1) the the­ory and prac­tice of vent­il­a­tion...
Ukraine sim­pli­fies li­cens­ing and per­mit­ting pro­ced­ures dur­ing mar­tial law
On 18 March 2022, the Cab­in­et of Min­is­ters of Ukraine ad­op­ted Res­ol­u­tion No. 314 “On Cer­tain Mat­ters for En­sur­ing Busi­ness Activ­ity Dur­ing Mar­tial Law”. For the dur­a­tion of mar­tial law, the Res­ol­u­tion...
New Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Man­u­fac­tur­ing
The Na­tion­al Mar­ket Su­per­vi­sion Ad­min­is­tra­tion ad­op­ted the Meas­ures on the Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices Man­u­fac­tur­ing (“Meas­ures”) on 10 March 2022, which will take ef­fect as...